Cancer Network Specifically, EURTAC randomized 165 patients between erlotinib and carboplatin/ gemcitabine , and showed a PFS improvement of 8.5 months (13.1 vs 4.6 months; P ... FDA Approves Frontline Erlotinib With Novel Companion Diagnostic for Advanced ... OncLive all 22 news articles »
globalnews.ca The extra saline in the bags containing cyclophosphamide and gemcitabine supplied to the hospitals effectively watered down the prescribed drug concentrations by up to 20 per cent. Some of the cancer patients were receiving the diluted drugs for as ... and more »
Healio Maintenance therapy with paclitaxel and gemcitabine improved PFS and OS in women with metastatic breast cancer who initially exhibited disease control after first-line treatment with six cycles of the same combination, according to results of a phase 3 ...
Healio Capecitabine demonstrated encouraging efficacy and toxicity outcomes compared with gemcitabine in a cohort of patients with locally advanced pancreatic cancer, according to phase 2 results of the SCALOP trial. Researchers conducted the open-label, ...
Toronto Star To date, 150 cancer patients who received the diluted treatment have died. It is unknown what, if any, role the weaker than prescribed doses of cyclophospha...
Healio Maintenance therapy with paclitaxel and gemcitabine improved PFS and OS in women with metastatic breast cancer who initially exhibited disease control after first-line treatment with six cycles of the same combination, according to results of a phase 3 ...
Windsor Star News broke a month ago that diluted doses of two chemotherapy drugs, cyclophosph-amide and gemcitabine , mixed and supplied by Marchese, had been administered to more than 1,200 cancer patients at four Ontario hospitals and one in New Brunswick.
Healio Capecitabine demonstrated encouraging efficacy and toxicity outcomes compared with gemcitabine in a cohort of patients with locally advanced pancreatic cancer, according to phase 2 results of the SCALOP trial. Researchers conducted the open-label, ...
Wall Street Journal (press release) Completion of enrollment and announcement of top line data for the NAPOLI-1 study, MM-398's global Phase 3 clinical trial in gemcitabine -resistant pancreatic cancer; -- Announcement of top line data from several MM-121 Phase 2 clinical trials focused ... and more »
